Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys

ABSTRACT SCH 56592 is a new broad-spectrum azole antifungal agent that is in phase 3 clinical trials for the treatment of serious systemic fungal infections. The pharmacokinetics of this drug candidate were evaluated following its intravenous (i.v.) or oral (p.o.) administration as a solution in hydroxypropyl-β-cyclodextrin (HPβCD) or oral administration as a suspension in 0.4% methylcellulose (MC) in studies involving mice, rats, rabbits, dogs, and cynomolgus monkeys. SCH 56592 was orally bioavailable in all species. The oral bioavailability was higher with the HPβCD solution (range, 52 to ∼100%) than from the MC suspension (range, 14 to 48%) and was higher in mice (∼100% [HPβCD] and 47% [MC]), rats (∼66% [HPβCD] and 48% [MC]), and dogs (72% [HPβCD] and 37% [MC]) than in monkeys (52% [HPβCD] and 14% [MC]). In rabbits, high concentrations in serum suggested good oral bioavailability with the MC suspension. The i.v. terminal-phase half-lives were 7 h in mice and rats, 15 h in dogs, and 23 h in monkeys. In rabbits, the oral half-life was 9 h. In species given increasing oral doses (mice, rats, and dogs), serum drug concentrations were dose related. Food produced a fourfold increase in serum drug concentrations in dogs. Multiple daily doses of 40 mg of SCH 56592/kg of body weight for eight consecutive days to fed dogs resulted in higher concentrations in serum, indicating accumulation upon multiple dosing, with an accumulation index of approximately 2.6. Concentrations above the MICs and minimum fungicidal concentrations for most organisms were observed at 24 h following a single oral dose in MC suspension in all five species studied (20 mg/kg for mice, rats, and rabbits and 10 mg/kg for dogs and monkeys), suggesting that once-daily administration of SCH 56592 in human subjects would be a therapeutically effective dosage regimen.

[1]  D. Stevens,et al.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis , 1997, Antimicrobial agents and chemotherapy.

[2]  D. Denning,et al.  Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus , 1997, Antimicrobial agents and chemotherapy.

[3]  D. Denning,et al.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp , 1997, Antimicrobial agents and chemotherapy.

[4]  M. Pfaller,et al.  Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae , 1997, Antimicrobial agents and chemotherapy.

[5]  A. Nomeir,et al.  Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended‐Release Tablets in Healthy Volunteers , 1996, Journal of clinical pharmacology.

[6]  J. Perfect,et al.  In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans , 1996, Antimicrobial agents and chemotherapy.

[7]  A. Sugar,et al.  In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis , 1996, Antimicrobial agents and chemotherapy.

[8]  M. Horowitz,et al.  Pharmacokinetic Considerations in Gastrointestinal Motor Disorders , 1995, Clinical pharmacokinetics.

[9]  D. Armstrong,et al.  Problems in management of opportunistic fungal diseases. , 1989, Reviews of infectious diseases.

[10]  T. Walsh,et al.  Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. , 1988, Annual review of microbiology.